{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:21:39Z","timestamp":1790270499789,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Research on intelligent recommendation decision model of geriatrics based on big data","award":["2021CXA001"],"award-info":[{"award-number":["2021CXA001"]}]},{"name":"Research on the development and prevention and control strategies of key viral infectious diseases in the post-COVID-19 era","award":["00902409"],"award-info":[{"award-number":["00902409"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82002457"],"award-info":[{"award-number":["82002457"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Young and Middle-aged Backbone Research Fund of Fujian Provincial Health Care Commission","award":["2019-ZQNB-1"],"award-info":[{"award-number":["2019-ZQNB-1"]}]},{"name":"the Natural Science Foundation of Fujian Province","award":["2023J01117"],"award-info":[{"award-number":["2023J01117"]}]},{"name":"Fujian Provincial Medical Science and Technology Innovation Joint Fund Project","award":["2020Y9023"],"award-info":[{"award-number":["2020Y9023"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14744-2","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T10:38:07Z","timestamp":1759228687000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The efficacy analysis of neoadjuvant chemoimmunotherapy followed by surgery in stage III locally advanced non-small cell lung cancer: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Xiaojie","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqiu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sufang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiongyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nengluan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongru","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"14744_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"14744_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71:209\u201349.","journal-title":"Cancer J Clin"},{"key":"14744_CR3","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1916623","volume":"383","author":"N Howlader","year":"2020","unstructured":"Howlader N, Forjaz G, Mooradian MJ, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383:640\u20139.","journal-title":"N Engl J Med"},{"key":"14744_CR4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.cllc.2022.02.001","volume":"23","author":"JP Harris","year":"2022","unstructured":"Harris JP, Fujimoto DK, Nagasaka M, et al. Controversies in lung cancer: heterogeneity in treatment recommendations for stage III NSCLC according to disease burden and oncogenic driver alterations. Clin Lung Cancer. 2022;23:333\u201344.","journal-title":"Clin Lung Cancer"},{"key":"14744_CR5","first-page":"1874","volume":"59","author":"CA Perez","year":"1987","unstructured":"Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Rep Radiation Therapy Oncol Group Cancer. 1987;59:1874\u201381.","journal-title":"Rep Radiation Therapy Oncol Group Cancer"},{"key":"14744_CR6","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","volume":"28","author":"A Aup\u00e9rin","year":"2010","unstructured":"Aup\u00e9rin A, Le P\u00e9choux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncology: Official J Am Soc Clin Oncol. 2010;28:2181\u201390.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"14744_CR7","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel DR, Faivre-Finn C, Gray JE, et al. Five-Year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III Non-Small-Cell lung cancer. J Clin Oncology: Official J Am Soc Clin Oncol. 2022;40:1301\u201311.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"14744_CR8","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/JCO.22.01989","volume":"41","author":"MC Garassino","year":"2023","unstructured":"Garassino MC, Gadgeel S, Speranza G, et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous Non-Small-Cell lung cancer: 5-Year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncology: Official J Am Soc Clin Oncol. 2023;41:1992\u20138.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"14744_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/jcph.591","volume":"56","author":"L Lee","year":"2016","unstructured":"Lee L, Gupta M, Sahasranaman S. Immune checkpoint inhibitors: an introduction to the next-generation cancer immunotherapy. J Clin Pharmacol. 2016;56:157\u201369.","journal-title":"J Clin Pharmacol"},{"key":"14744_CR10","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973\u201385.","journal-title":"N Engl J Med"},{"key":"14744_CR11","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","volume":"27","author":"T Cascone","year":"2021","unstructured":"Cascone T, William WN Jr., Weissferdt A, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021;27:504\u201314.","journal-title":"Nat Med"},{"key":"14744_CR12","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","volume":"21","author":"M Provencio","year":"2020","unstructured":"Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:1413\u201322.","journal-title":"Lancet Oncol"},{"key":"14744_CR13","doi-asserted-by":"publisher","first-page":"e600","DOI":"10.1097\/SLA.0000000000005233","volume":"275","author":"H Deng","year":"2022","unstructured":"Deng H, Liu J, Cai X, et al. Radical minimally invasive surgery after Immuno-chemotherapy in Initially-unresectable stage IIIB Non-small cell lung cancer. Ann Surg. 2022;275:e600\u20132.","journal-title":"Ann Surg"},{"key":"14744_CR14","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jama.2023.24735","volume":"331","author":"S Lu","year":"2024","unstructured":"Lu S, Zhang W, Wu L, et al. Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the neotorch randomized clinical trial. JAMA. 2024;331:201\u201311.","journal-title":"JAMA"},{"key":"14744_CR15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.21037\/tlcr-22-75","volume":"11","author":"J Jiang","year":"2022","unstructured":"Jiang J, Wang Y, Gao Y, et al. Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis. Transl Lung Cancer Res. 2022;11:277\u201394.","journal-title":"Transl Lung Cancer Res"},{"key":"14744_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.21037\/jtd-21-1664","volume":"14","author":"S Ge","year":"2022","unstructured":"Ge S, Huang C. Immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer: a systematic review and meta-analysis. J Thorac Disease. 2022;14:333\u201342.","journal-title":"J Thorac Disease"},{"key":"14744_CR17","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1200\/JCO.21.02660","volume":"40","author":"M Provencio","year":"2022","unstructured":"Provencio M, Serna-Blasco R, Nadal E, et al. Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA Non-Small-Cell lung cancer (NADIM phase II trial). J Clin Oncology: Official J Am Soc Clin Oncol. 2022;40:2924\u201333.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"14744_CR18","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.21.00276","volume":"39","author":"SI Rothschild","year":"2021","unstructured":"Rothschild SI, Zippelius A, Eboulet EI, et al. SAKK 16\/14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) Non-Small-Cell lung Cancer-A multicenter Single-Arm phase II trial. J Clin Oncology: Official J Am Soc Clin Oncol. 2021;39:2872\u201380.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"14744_CR19","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.21037\/jtd-21-103","volume":"13","author":"D Shen","year":"2021","unstructured":"Shen D, Wang J, Wu J, et al. Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB-IIIB resectable lung squamous cell carcinoma. J Thorac Disease. 2021;13:1760\u20138.","journal-title":"J Thorac Disease"},{"key":"14744_CR20","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00432-021-03896-w","volume":"149","author":"C Sun","year":"2023","unstructured":"Sun C, Liu Y, Zhang P, et al. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA\/IIIB non-small cell lung cancer: a single-arm, phase 2 trial. J Cancer Res Clin Oncol. 2023;149:819\u201331.","journal-title":"J Cancer Res Clin Oncol"},{"key":"14744_CR21","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.athoracsur.2022.01.039","volume":"114","author":"P Zhang","year":"2022","unstructured":"Zhang P, Dai J, Sun F, et al. Neoadjuvant sintilimab and chemotherapy for resectable stage IIIA non-small cell lung cancer. Ann Thorac Surg. 2022;114:949\u201358.","journal-title":"Ann Thorac Surg"},{"key":"14744_CR22","doi-asserted-by":"publisher","first-page":"S1014","DOI":"10.1016\/j.jtho.2021.08.339","volume":"16","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zeng L, Zhang X, et al. P15.02 Toripalimab and Platinum-Doublet chemotherapy as neoadjuvant therapy for potentially resectable Non-Small cell lung cancer. J Thorac Oncol. 2021;16:S1014\u20135.","journal-title":"J Thorac Oncol"},{"key":"14744_CR23","doi-asserted-by":"publisher","first-page":"1996000","DOI":"10.1080\/2162402X.2021.1996000","volume":"10","author":"ZR Zhao","year":"2021","unstructured":"Zhao ZR, Yang CP, Chen S, et al. Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer. Oncoimmunology. 2021;10:1996000.","journal-title":"Oncoimmunology"},{"key":"14744_CR24","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1186\/s12916-022-02696-4","volume":"20","author":"X Zhu","year":"2022","unstructured":"Zhu X, Sun L, Song N, et al. Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial. BMC Med. 2022;20:493.","journal-title":"BMC Med"},{"key":"14744_CR25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12916-024-03462-4","volume":"22","author":"J Shan","year":"2024","unstructured":"Shan J, Liu Z, Chen S, et al. Optimizing perioperative treatment for potentially resectable stage III squamous cell lung carcinoma: promising results of a condensed four-cycle regimen with Tislelizumab and chemotherapy. BMC Med. 2024;22:234.","journal-title":"BMC Med"},{"key":"14744_CR26","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1001\/jamaoncol.2023.2751","volume":"9","author":"J Lei","year":"2023","unstructured":"Lei J, Zhao J, Gong L, et al. Neoadjuvant camrelizumab plus platinum-based chemotherapy vs chemotherapy alone for Chinese patients with resectable stage IIIA or IIIB (T3N2) non-small cell lung cancer: the TD-FOREKNOW randomized clinical trial. JAMA Oncol. 2023;9:1348\u201355.","journal-title":"JAMA Oncol"},{"key":"14744_CR27","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.athoracsur.2021.03.041","volume":"113","author":"T Chen","year":"2022","unstructured":"Chen T, Ning J, Campisi A, et al. Neoadjuvant PD-1 inhibitors and chemotherapy for locally advanced NSCLC: a retrospective study. Ann Thorac Surg. 2022;113:993\u20139.","journal-title":"Ann Thorac Surg"},{"key":"14744_CR28","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.21037\/tlcr-21-329","volume":"10","author":"Y Chen","year":"2021","unstructured":"Chen Y, Yan B, Xu F, et al. Neoadjuvant chemoimmunotherapy in resectable stage IIIA\/IIIB non-small cell lung cancer. Transl Lung Cancer Res. 2021;10:2193\u2013204.","journal-title":"Transl Lung Cancer Res"},{"key":"14744_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.956755","volume":"12","author":"L Shi","year":"2022","unstructured":"Shi L, Meng Q, Tong L, et al. Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell lung cancer. Front Oncol. 2022;12: 956755.","journal-title":"Front Oncol"},{"key":"14744_CR30","doi-asserted-by":"publisher","first-page":"486","DOI":"10.21037\/atm-21-670","volume":"9","author":"J Wang","year":"2021","unstructured":"Wang J, Li J, Cai L, Chen S, Jiang Y. The safety and efficacy of neoadjuvant programmed death 1 inhibitor therapy with surgical resection in stage IIIA non-small cell lung cancer. Annals Translational Med. 2021;9:486.","journal-title":"Annals Translational Med"},{"key":"14744_CR31","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1055\/s-0042-1758552","volume":"71","author":"Y Wang","year":"2023","unstructured":"Wang Y, He C, Liu J, et al. The safety and efficacy of preoperative immunotherapy combined with chemotherapy in patients with stage IIIA-IIIB lung squamous cell carcinoma. Thorac Cardiovasc Surg. 2023;71:222\u201330.","journal-title":"Thorac Cardiovasc Surg"},{"key":"14744_CR32","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.2147\/DDDT.S388777","volume":"16","author":"H Xu","year":"2022","unstructured":"Xu H, Wang W, Yin J, Song C, Li L, Sun Z. Efficacy and safety of the PD-1 inhibitor combined with albumin-bound paclitaxel and nedaplatin in preoperative neoadjuvant therapy of unresectable stage III lung squamous cell carcinoma. Drug Des Devel Ther. 2022;16:4269\u201377.","journal-title":"Drug Des Devel Ther"},{"key":"14744_CR33","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2147\/CMAR.S344343","volume":"14","author":"H Zhai","year":"2022","unstructured":"Zhai H, Li W, Jiang K, Zhi Y, Yang Z. Neoadjuvant nivolumab and chemotherapy in patients with locally advanced non-small cell lung cancer: a retrospective study. Cancer Manag Res. 2022;14:515\u201324.","journal-title":"Cancer Manag Res"},{"key":"14744_CR34","doi-asserted-by":"publisher","first-page":"141","DOI":"10.21037\/tlcr-22-871","volume":"12","author":"G Zhao","year":"2023","unstructured":"Zhao G, Zhang H, Xu F, et al. Neoadjuvant pembrolizumab and chemotherapy in resectable clinical stage III non-small-cell lung cancer: a retrospective cohort study. Transl Lung Cancer Res. 2023;12:141\u20139.","journal-title":"Transl Lung Cancer Res"},{"key":"14744_CR35","doi-asserted-by":"publisher","first-page":"1343504","DOI":"10.3389\/fimmu.2023.1343504","volume":"14","author":"S Zhou","year":"2023","unstructured":"Zhou S, Liu Y, Liu K, et al. Comparison of neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable stage III non-small cell lung cancer: a real-world cohort study. Front Immunol. 2023;14:1343504.","journal-title":"Front Immunol"},{"key":"14744_CR36","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.21037\/tlcr.2017.12.12","volume":"7","author":"F Agustoni","year":"2018","unstructured":"Agustoni F, Hirsch FR. PACIFIC trial: new perspectives for immunotherapy in lung cancer. Transl Lung Cancer Res. 2018;7:S19\u201324.","journal-title":"Transl Lung Cancer Res"},{"key":"14744_CR37","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","volume":"15","author":"MD Hellmann","year":"2014","unstructured":"Hellmann MD, Chaft JE, William WN Jr., et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014;15:e42\u201350.","journal-title":"Lancet Oncol"},{"key":"14744_CR38","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41571-019-0173-9","volume":"16","author":"DR Camidge","year":"2019","unstructured":"Camidge DR, Doebele RC, Kerr KM. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol. 2019;16:341\u201355.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14744-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14744-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14744-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:30:29Z","timestamp":1759275029000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14744-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14744"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14744-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"2 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1443"}}